NCT05463796 2025-08-07InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for CancerDana-Farber Cancer InstituteRecruiting5,000 enrolled
NCT04666090 2025-05-15Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell CarcinomaSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityPhase 2 Active not recruiting42 enrolled